State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy

This paper deals with the second phase of the prospective, randomized comparative study of the efficacy and safety of the hybrid eradication therapy (ET) regimen in patients with H. pylori-associated gastroduodenal ulcer. Objective: Evaluation of the acid-forming function of the stomach with a pharm...

Full description

Bibliographic Details
Main Authors: G. L. Yurenev, E. V. Partsvania-Vinogradova, D. N. Andreev, D. T. Dicheva, I. V. Maev
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-04-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/2395
id doaj-94d4c59935974f819c8ab49557ecdcd7
record_format Article
spelling doaj-94d4c59935974f819c8ab49557ecdcd72021-07-28T13:29:35ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-04-010617417910.21518/2079-701X-2018-6-174-1792370State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapyG. L. Yurenev0E. V. Partsvania-Vinogradova1D. N. Andreev2D. T. Dicheva3I. V. Maev4Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of RussiaYevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of RussiaYevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of RussiaYevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of RussiaYevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of RussiaThis paper deals with the second phase of the prospective, randomized comparative study of the efficacy and safety of the hybrid eradication therapy (ET) regimen in patients with H. pylori-associated gastroduodenal ulcer. Objective: Evaluation of the acid-forming function of the stomach with a pharmacological proton pump inhibitor (PPI) test in patients with H. pylori-associated gastroduodenal ulcer disease and no response to eradication therapy. Materials and methods. 19 patients were enrolled in this study after the failed ET using any of the following three regimens: standard triple regimen, four-component therapy with bismuth agents, hybrid regimen; in all regimens, omeprazole (20 mg b.i.d.) was used as an IPP. All patients underwent a 48-hour intragastric pH-meter (Gastroscan-GEM device, Istok-System, Russia) to assess the initial state of the acid-forming function of the stomach during the first day and the subsequent pharmacological PPI test (omeprazole 20 mg b.i.d.) on the second day. The minimum, maximum and average pH values in the cardia and body of the stomach, as well as the time with pH> 4 in the body of the stomach during the entire study period (48 hours) were analysed. Results. Median time average with pH> 4 in the body of the stomach for the first day of the study (before PPI administration) was 1.0 hour (IQR from 0.0 to 1.5), and against a pharmacological test – 15.5 hours (IQR from 11.1 to 16.5). At the same time, an adequate alkalization of the gastric environment under pressure of IPP therapy was identified in 12 patients, when the pH level> 4 in the body of the stomach was maintained for 16–17 hours. In 7 patients, pH> 4 was maintained for less than 16 hours, which is a symptom of insufficient antisecretory effect. During this study, no PPI resistance was revealed. The conclusion. Evaluation of the state of the acid-forming function of the stomach with pharmacological tests upon conduct of the 48-hour pH-metry makes it possible to evaluate the antisecretory effect of the used PPI and, thus, to predict the probability of effective eradication.https://www.med-sovet.pro/jour/article/view/2395helicobacter pylorieradication therapyulcer diseasehybrid therapytriple therapyfour-component therapydaily ph-metrypharmacological test
collection DOAJ
language Russian
format Article
sources DOAJ
author G. L. Yurenev
E. V. Partsvania-Vinogradova
D. N. Andreev
D. T. Dicheva
I. V. Maev
spellingShingle G. L. Yurenev
E. V. Partsvania-Vinogradova
D. N. Andreev
D. T. Dicheva
I. V. Maev
State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy
Медицинский совет
helicobacter pylori
eradication therapy
ulcer disease
hybrid therapy
triple therapy
four-component therapy
daily ph-metry
pharmacological test
author_facet G. L. Yurenev
E. V. Partsvania-Vinogradova
D. N. Andreev
D. T. Dicheva
I. V. Maev
author_sort G. L. Yurenev
title State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy
title_short State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy
title_full State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy
title_fullStr State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy
title_full_unstemmed State of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy
title_sort state of acid-producing function of the stomach in patients with helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2018-04-01
description This paper deals with the second phase of the prospective, randomized comparative study of the efficacy and safety of the hybrid eradication therapy (ET) regimen in patients with H. pylori-associated gastroduodenal ulcer. Objective: Evaluation of the acid-forming function of the stomach with a pharmacological proton pump inhibitor (PPI) test in patients with H. pylori-associated gastroduodenal ulcer disease and no response to eradication therapy. Materials and methods. 19 patients were enrolled in this study after the failed ET using any of the following three regimens: standard triple regimen, four-component therapy with bismuth agents, hybrid regimen; in all regimens, omeprazole (20 mg b.i.d.) was used as an IPP. All patients underwent a 48-hour intragastric pH-meter (Gastroscan-GEM device, Istok-System, Russia) to assess the initial state of the acid-forming function of the stomach during the first day and the subsequent pharmacological PPI test (omeprazole 20 mg b.i.d.) on the second day. The minimum, maximum and average pH values in the cardia and body of the stomach, as well as the time with pH> 4 in the body of the stomach during the entire study period (48 hours) were analysed. Results. Median time average with pH> 4 in the body of the stomach for the first day of the study (before PPI administration) was 1.0 hour (IQR from 0.0 to 1.5), and against a pharmacological test – 15.5 hours (IQR from 11.1 to 16.5). At the same time, an adequate alkalization of the gastric environment under pressure of IPP therapy was identified in 12 patients, when the pH level> 4 in the body of the stomach was maintained for 16–17 hours. In 7 patients, pH> 4 was maintained for less than 16 hours, which is a symptom of insufficient antisecretory effect. During this study, no PPI resistance was revealed. The conclusion. Evaluation of the state of the acid-forming function of the stomach with pharmacological tests upon conduct of the 48-hour pH-metry makes it possible to evaluate the antisecretory effect of the used PPI and, thus, to predict the probability of effective eradication.
topic helicobacter pylori
eradication therapy
ulcer disease
hybrid therapy
triple therapy
four-component therapy
daily ph-metry
pharmacological test
url https://www.med-sovet.pro/jour/article/view/2395
work_keys_str_mv AT glyurenev stateofacidproducingfunctionofthestomachinpatientswithhelicobacterpyloriassociatedgastroduodenalulcerdiseaseandnoresponsetoeradicationtherapy
AT evpartsvaniavinogradova stateofacidproducingfunctionofthestomachinpatientswithhelicobacterpyloriassociatedgastroduodenalulcerdiseaseandnoresponsetoeradicationtherapy
AT dnandreev stateofacidproducingfunctionofthestomachinpatientswithhelicobacterpyloriassociatedgastroduodenalulcerdiseaseandnoresponsetoeradicationtherapy
AT dtdicheva stateofacidproducingfunctionofthestomachinpatientswithhelicobacterpyloriassociatedgastroduodenalulcerdiseaseandnoresponsetoeradicationtherapy
AT ivmaev stateofacidproducingfunctionofthestomachinpatientswithhelicobacterpyloriassociatedgastroduodenalulcerdiseaseandnoresponsetoeradicationtherapy
_version_ 1721274055957413888